Temperature-controlled supply chain solutions firm Cryoport has partnered with VGCI, a subsidiary of GeneOne Life Science, to support the development of cell and gene therapies and mRNA-based treatments.
Under terms of the deal, Cryoport will provide biostorage and bioservices for plasmid DNA products manufactured at VGXI’s facilities in the Woodlands, Texas, and its headquarters and manufacturing location, also in Texas.
Jerrell Shelton, CEO of Cryoport, said the partnership underscores the company’s shared commitment to quality and innovation in the cell and gene market.
“Together, we will provide biopharmaceutical companies a comprehensive and integrated solution to support clinical programmes that are developing lifesaving, next-generation therapeutic modalities.”
Partnership operations are set to commence in October 2024.
Young Park, CEO of VGXI, added, “We are thrilled to launch this partnership to support our client’s advanced therapy programmes, including cell and gene therapies, mRNA-based treatments and DNA vaccines.”
According to Nova One Advisor, the global cell and gene therapy market size was valued at $18.13bn in 2023 but is expected to reach around $97.33bn in 2033, growing at a CAGR of 18.3% from 2024 to 2033.
The life sciences industry requires a robust shipping system, at cryogenic temperatures that can handle the risks associated with transporting high-value commodities such as advanced therapies. Slight temperature deviations can render the commodity ineffective, and minor physical damage can also damage its usability.
With so much at stake, advanced therapy developers and manufacturers need an advanced packaging system that can maintain consistent temperatures to deliver raw materials, viral vectors, and gene therapies in perfect condition.
News of the deal follows Cryoport last week opening a new facility at its integrated supply chain campus in Houston, Texas, to develop its IntegriCell™ cryopreservation services solution.
Read more: Cryoport opens Houston site for IntegriCell cryopreservation
IntegriCell is a standardised bioprocessing, cryopreservation, and distribution solution for the global cell and gene therapy market. The platform is designed to enhance cell therapy manufacturing and flexibility to support lifesaving treatments.
The new facility will specifically focus on the standardised cryopreservation of leukapheresis material. The new offering will be integrated into Cryoport’s temperature-controlled supply chain platform.
European CO2 Summit 2025: Rotterdam
The conversation around carbon dioxide (CO2) is changing, with a focus on its value as part of a circular economy. Join The European CO2 Summit in Rotterdam this March to explore the future of the CO2 business in Europe and its alignment with decarbonisation efforts. Expect market insights, emerging technologies, panel discussions, and networking opportunities.
Learn more: https://bit.ly/Europeanco2summit2025-F
